SS-31 / Elamipretide Research Evidence Map: Models, Questions and Evidence Limits

Research Identity

This evidence map treats SS-31 / Elamipretide as a modified tetrapeptide studied in mitochondrial membrane and cardiolipin research. The identity of the material and the model used in a paper should be established before findings are generalized.

Major Research Areas

• cardiolipin interaction
• mitochondrial membrane biology
• bioenergetic models
• translational and clinical-development literature

What the Literature Can Establish

SS-31, also known as elamipretide in pharmaceutical-development contexts, has a substantial literature spanning mechanistic and translational research.

Biochemical assays can support mechanism, cellular experiments can test pathway responses, animal models add organism-level complexity, and human studies answer different translational questions. Each evidence level should remain labeled.

What Remains Uncertain or Model-Dependent?

Findings from a regulated pharmaceutical product or specific clinical formulation should not automatically be generalized to unrelated laboratory research materials.

Evidence-Quality Checklist

• Was the exact compound or formulation identified?
• Was the experimental model clearly described?
• Were appropriate negative, vehicle or positive controls used?
• Were the measured endpoints appropriate to the conclusion?
• Has the observation been replicated independently?
• Does the source distinguish mechanism from clinical or organism-level outcome?

Reference Pathways

Use the original paper whenever a specific finding is discussed. Database searches are starting points, not substitutes for reading the underlying study.

• PubMed literature search
• PubChem chemical and molecular records
• NCBI Bookshelf scientific reference resources